Latest News

STAT Plus: 23andMe’s chief scientific officer, a star in drug development, is leaving role

The chief scientific officer at 23andMe is leaving his role at the consumer genetics company, four years after his arrival helped energize its move toward drug discovery.

Richard Scheller, a Genentech veteran, has joined the Palo Alto, Calif.-based BridgeBio (BBIO) as chairman of research and development, according to Securities and Exchange Commission filings. Scheller remains on 23andMe’s board of directors. 

Continue to STAT Plus to read the full story…

Source link

Related posts

Neurocomputational Accounts of Choice Variability and Affect during Decision-making


New 3-D imaging technique shows promise for finding contractions that may lead to early birth


Former inmates at high risk for opioid overdose following prison release


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy